Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data.

Authors:
Jyotsna Batra
Jyotsna Batra
Institute of Health and Biomedical Innovation and School of Biomedical Science
Kelvin Grove | Australia
Felicity Lose
Felicity Lose
Queensland Institute of Medical Research
Australia
Louise Marquart
Louise Marquart
Queensland Institute of Medical Research
Australia
Carson Stephens
Carson Stephens
Queensland University of Technology
Australia
Kimberly Alexander
Kimberly Alexander
School of Nursing
Australia
Srilakshmi Srinivasan
Srilakshmi Srinivasan
Queensland University of Technology
Australia
Rosalind A Eeles
Rosalind A Eeles
The Institute of Cancer Research
United Kingdom

PLoS One 2011 23;6(11):e26527. Epub 2011 Nov 23.

Australian Prostate Cancer Research Centre-Queensland and Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.

Background: Kallikrein 15 (KLK15)/Prostinogen is a plausible candidate for prostate cancer susceptibility. Elevated KLK15 expression has been reported in prostate cancer and it has been described as an unfavorable prognostic marker for the disease.

Objectives: We performed a comprehensive analysis of association of variants in the KLK15 gene with prostate cancer risk and aggressiveness by genotyping tagSNPs, as well as putative functional SNPs identified by extensive bioinformatics analysis. METHODS AND DATA SOURCES: Twelve out of 22 SNPs, selected on the basis of linkage disequilibrium pattern, were analyzed in an Australian sample of 1,011 histologically verified prostate cancer cases and 1,405 ethnically matched controls. Replication was sought from two existing genome wide association studies (GWAS): the Cancer Genetic Markers of Susceptibility (CGEMS) project and a UK GWAS study.

Results: Two KLK15 SNPs, rs2659053 and rs3745522, showed evidence of association (p<0.05) but were not present on the GWAS platforms. KLK15 SNP rs2659056 was found to be associated with prostate cancer aggressiveness and showed evidence of association in a replication cohort of 5,051 patients from the UK, Australia, and the CGEMS dataset of US samples. A highly significant association with Gleason score was observed when the data was combined from these three studies with an Odds Ratio (OR) of 0.85 (95% CI = 0.77-0.93; p = 2.7×10(-4)). The rs2659056 SNP is predicted to alter binding of the RORalpha transcription factor, which has a role in the control of cell growth and differentiation and has been suggested to control the metastatic behavior of prostate cancer cells.

Conclusions: Our findings suggest a role for KLK15 genetic variation in the etiology of prostate cancer among men of European ancestry, although further studies in very large sample sets are necessary to confirm effect sizes.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0026527PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223160PMC
April 2012
11 Reads
2 PubMed Central Citations(source)
3.23 Impact Factor

Publication Analysis

Top Keywords

prostate cancer
20
cancer risk
8
risk aggressiveness
8
cancer
6
prostate
5
data sources
4
selected basis
4
sources twelve
4
snps selected
4
twelve snps
4
basis linkage
4
australian sample
4
sample 1011
4
1011 histologically
4
analyzed australian
4
pattern analyzed
4
linkage disequilibrium
4
disequilibrium pattern
4
methods data
4
extensive bioinformatics
4

Similar Publications

Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness.

Urol Oncol 2013 Jul 8;31(5):635-43. Epub 2011 Jul 8.

Molecular Cancer Epidemiology group, Genetics and Population Health Division, Queensland Institute of Medical Research, Brisbane, Queensland, Australia.

The human tissue Kallikrein family consists of 15 genes with the majority shown to be differentially expressed in cancers and/or indicators of cancer prognosis. We sought to elucidate the role of common genetic variation in four of the Kallikrein genes, KLK5, KLK6, KLK12, and KLK13, in prostate cancer risk and tumor aggressiveness. Genotyping of all 22 tagging single nucleotide polymorphisms (tagSNPs) in the KLK5, KLK6, KLK12, and KLK13 genes was performed in approximately 1,000 prostate cancer cases and 1,300 male controls from Australia. Read More

View Article
July 2013

A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival.

BMC Cancer 2011 Apr 1;11:119. Epub 2011 Apr 1.

Australian Prostate Cancer Research centre-Queensland and Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, Brisbane, Queensland 4059, Australia.

Background: KLK15 over-expression is reported to be a significant predictor of reduced progression-free survival and overall survival in ovarian cancer. Our aim was to analyse the KLK15 gene for putative functional single nucleotide polymorphisms (SNPs) and assess the association of these and KLK15 HapMap tag SNPs with ovarian cancer survival.

Results: In silico analysis was performed to identify KLK15 regulatory elements and to classify potentially functional SNPs in these regions. Read More

View Article
April 2011

Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans.

Prostate 2013 Jan 1;73(1):11-22. Epub 2012 May 1.

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Background: Genome-wide association studies have established a number of replicated single nucleotide polymorphisms (SNPs) for susceptibility to prostate cancer (CaP), but it is unclear whether these susceptibility SNPs are also associated with disease aggressiveness. This study evaluates whether such replication SNPs or other candidate SNPs are associated with CaP aggressiveness in African-American (AA) and European-American (EA) men.

Methods: A 1,536 SNP panel which included 34 genome-wide association study (GWAS) replication SNPs, 38 flanking SNPs, a set of ancestry informative markers, and SNPs in candidate genes and other areas was genotyped in 1,060 AA and 1,087 EA men with incident CaP from the North Carolina-Louisiana Prostate Cancer Project (PCaP). Read More

View Article
January 2013

Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript.

Hum Genet 2011 Jun 5;129(6):687-94. Epub 2011 Apr 5.

The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK.

Genome-wide association studies (GWAS) have identified more than 30 prostate cancer (PrCa) susceptibility loci. One of these (rs2735839) is located close to a plausible candidate susceptibility gene, KLK3, which encodes prostate-specific antigen (PSA). PSA is widely used as a biomarker for PrCa detection and disease monitoring. Read More

View Article
June 2011